Cargando…

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

AIMS/HYPOTHESIS: In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritz, E., Viberti, G. C., Ruilope, L. M., Rabelink, A. J., Izzo, J. L., Katayama, S., Ito, S., Mimran, A., Menne, J., Rump, L. C., Januszewicz, A., Haller, H.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789932/
https://www.ncbi.nlm.nih.gov/pubmed/19876613
http://dx.doi.org/10.1007/s00125-009-1577-3
_version_ 1782175074410823680
author Ritz, E.
Viberti, G. C.
Ruilope, L. M.
Rabelink, A. J.
Izzo, J. L.
Katayama, S.
Ito, S.
Mimran, A.
Menne, J.
Rump, L. C.
Januszewicz, A.
Haller, H.
author_facet Ritz, E.
Viberti, G. C.
Ruilope, L. M.
Rabelink, A. J.
Izzo, J. L.
Katayama, S.
Ito, S.
Mimran, A.
Menne, J.
Rump, L. C.
Januszewicz, A.
Haller, H.
author_sort Ritz, E.
collection PubMed
description AIMS/HYPOTHESIS: In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk. METHODS: At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed. RESULTS: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r (s) = 0.19); HbA(1c) (r (s) = 0.18); mean 24 h systolic BP (r (s) = 0.16); fasting blood glucose (r (s) = 0.16); night-time diastolic BP (r (s) = 0.12); office systolic BP, sitting (r (s) = 0.11), standing (r (s) = 0.10); estimated GFR (r (s) = 0.10); heart rate, sitting (r (s) = 0.10); haemoglobin (r (s) = −0.10); triacylglycerol (r (s) = 0.09); and uric acid (r (s) = −0.08; all p ≤ 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women). CONCLUSIONS/INTERPRETATION: Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention. TRIAL REGISTRATION: ClinicalTrials.gov ID no.: NCT00185159 FUNDING: This study was sponsored by Daichii-Sankyo.
format Text
id pubmed-2789932
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-27899322009-12-15 Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study Ritz, E. Viberti, G. C. Ruilope, L. M. Rabelink, A. J. Izzo, J. L. Katayama, S. Ito, S. Mimran, A. Menne, J. Rump, L. C. Januszewicz, A. Haller, H. Diabetologia Article AIMS/HYPOTHESIS: In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk. METHODS: At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed. RESULTS: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r (s) = 0.19); HbA(1c) (r (s) = 0.18); mean 24 h systolic BP (r (s) = 0.16); fasting blood glucose (r (s) = 0.16); night-time diastolic BP (r (s) = 0.12); office systolic BP, sitting (r (s) = 0.11), standing (r (s) = 0.10); estimated GFR (r (s) = 0.10); heart rate, sitting (r (s) = 0.10); haemoglobin (r (s) = −0.10); triacylglycerol (r (s) = 0.09); and uric acid (r (s) = −0.08; all p ≤ 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women). CONCLUSIONS/INTERPRETATION: Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention. TRIAL REGISTRATION: ClinicalTrials.gov ID no.: NCT00185159 FUNDING: This study was sponsored by Daichii-Sankyo. Springer-Verlag 2009-10-30 2010 /pmc/articles/PMC2789932/ /pubmed/19876613 http://dx.doi.org/10.1007/s00125-009-1577-3 Text en © The Author(s) 2009 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Ritz, E.
Viberti, G. C.
Ruilope, L. M.
Rabelink, A. J.
Izzo, J. L.
Katayama, S.
Ito, S.
Mimran, A.
Menne, J.
Rump, L. C.
Januszewicz, A.
Haller, H.
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title_full Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title_fullStr Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title_full_unstemmed Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title_short Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
title_sort determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the randomised olmesartan and diabetes microalbuminuria prevention (roadmap) study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789932/
https://www.ncbi.nlm.nih.gov/pubmed/19876613
http://dx.doi.org/10.1007/s00125-009-1577-3
work_keys_str_mv AT ritze determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT vibertigc determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT ruilopelm determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT rabelinkaj determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT izzojl determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT katayamas determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT itos determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT mimrana determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT mennej determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT rumplc determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT januszewicza determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy
AT hallerh determinantsofurinaryalbuminexcretionwithinthenormalrangeinpatientswithtype2diabetestherandomisedolmesartananddiabetesmicroalbuminuriapreventionroadmapstudy